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Supplementary Note
Genome-wide association meta-analyses combining multiple risk phenotypes provides insights
into the genetic architecture of cutaneous melanoma susceptibility
1
Inclusion of self-report cases
Before combining the two self-report sets and the clinically confirmed GWAS data, we used LDSC1
to investigate the genetic correlation (Rg) between self-reported CM cases and the confirmed-only 
cases from the meta-analysis GWAS data (Supplementary Note, Supplementary Table 2). 
Correlations with clinically confirmed CM GWAS results were high, with the self-report 23andMe, 
Inc. and UK Biobank (UKBB) GWAS yielding Rg of 1.00 (SE = 0.13) and 0.65 (SE = 0.15), 
respectively (Supplementary Table 2). While the Rg for the UKBB self-reported cases may be 
lower as all UKBB self-reported cases that could be confirmed by cancer registries were moved into
the UKBB confirmed set, LDSC estimates can be imprecise when the effective sample size is less 
than 5,000 (Online Methods, Supplementary Table 1). 
Moreover, the confidence intervals between the UKBB self-report and 23andMe overlapped 
substantially (UKBB self-report Rg=0.65, 95% CI=0.36-0.95; 23andMe Rg=1.00 95% CI=0.74-
1.00). This suggests that the UK Biobank self-report GWAS does not differ in terms of genetic 
architecture from the other CM GWAS. 
Looking specifically at the lead SNPs identified in the confirmed only meta-analysis 
(Supplementary Table 6), the correlation of log(OR) beta estimates (weighted by their inverse 
variance) from the confirmed only meta-analysis and from the UKBB self-report set is high, r2 = 
0.62 (Extended Data Figure 6). As a further sensitivity analysis, we excluded the UKBB self-
report set from the meta-analysis, retaining all confirmed sets and 23andMe. Three loci found in the
total (all confirmed sets plus 23andMe and UKBB self-report) no longer reached genome-wide 
significance. Heterogeneity was low across these loci (I2 <= 10%), both with and without the UKBB
self-report set, suggesting its presence was improving power without driving the discovery of these 
loci nor leading to heterogeneity. For each of these three lead SNPs the estimate within UKBB self-
report was consistent with the wider meta-analysis (Supplementary Table 18). For example, 
rs6908626 in the UKBB self-report had a log(OR) = 0.151, and a 95% CI = 0.047 - 0.255. In the 
meta-analysis without UKBB self-report the log(OR) = 0.078 , 95% CI = 0.049 - 0.107, with 
overlapping confidence intervals. The consistency of UKBB self-report GWAS at these three loci is
further supported by the reported forest plots for these SNPs in Supplementary Figure 2. These 
show that log(OR) estimates from UKBB self-report set are consistent with, and overlap, those of 
other confirmed case sets.
Thus, although the Rg between UKBB self-report and the confirmed meta-GWAS is not 1 (which 
may be for a range of reasons e.g., LD score regression power), the inclusion of the UKBB self-
report GWAS boosts the power to identify new melanoma GWAS loci without introducing bias.
Replication of previously reported melanoma GWAS loci
Our analysis directly confirms 19 of the 21 loci reaching genome-wide significance in a previous 
CM GWAS2-9 (Table 1). The previously reported peak variant for the locus in intron 8 of FTO 
rs16953002 did not formally replicate (Pmeta_r = 1.2 × 10−6, I2 = 35%, Pmeta = 3.8 ×10−8) nor did any 
SNPs in LD, with the most strongly associated SNP at this region being rs62034121. However, 
rs16953002 and rs62034121 are in LD (r2EUR = 0.96), and these variants are genome-wide 
significant in the meta-analysis of confirmed-only CM cases, and the combined CM plus nevus 
analysis (see below and Online Methods). A recent melanoma GWAS9 reported rs187843643 near 
BASP1 as a melanoma locus; while we included the contributing GWAS study in our analysis, this 
locus was no longer genome-wide significant in the meta-analysis (I2 = 35%, Pmeta_r = 0.3, Pmeta = 
0.00071). 
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The previously reported CM susceptibility variant centromeric to AGR3 (rs1636744) on 
chromosome 7 is still significantly associated with CM, but is no longer the regional peak. While a 
SNP in LD (r2EUR = 0.91) with rs1636744, rs73069846, is an independent risk variant for CM 
(Supplementary Table 3) the peak variant for this locus is now rs117132860 (r2EUR < 0.03 with 
previously reported variants) located near the AHR gene (Table 1, Supplementary Table 3; Pmeta= 
3.8 × 10-21). This region exhibits a complex LD structure and more focused investigations are 
needed to disentangle the CM association(s) in this region. Similarly, the peak variant near IRF4 is 
rs12215602 and not the previously reported rs12203592, for which substantial heterogeneity was 
observed (I2 = 81%, Pmeta_R = 0.1, Pmeta = 1.9 × 10-13).
The total CM meta-analysis also confirmed 6 regions previously identified only by combining 
nevus count and CM GWAS data10 (Table 2). While in our CM meta-analysis the peak variant for 
another region near MFSD12 and FZR1, rs12984831, is independent from the previously-reported 
peak at rs34466956 (r2EUR = 0.001), rs34466956 is also significantly associated in our combined 
analysis of CM and nevus count described below (PCM+nevus = 2.5 × 10-9; Supplementary Table 7).  
Meta-analysis of pathologically confirmed-only melanoma GWAS
The meta-analysis for pathologically confirmed-only CM cases (N=30,134; Supplementary Table 
1) identified a total of 46 loci associated with CM susceptibility (Supplementary Table 6, 
Extended Data Figures 2-3). Three loci were significant in the confirmed-only CM and not the 
total CM analysis. The first, on chromosome 4, rs2301293 (confirmed Pmeta=3.2×10-9, OR=0.89, 
I2=0%) while not significant in the total CM meta-analysis, showed negligible difference in its 
estimate (Pmeta=5.8×10-8, I2=11%, OR=0.91). The second locus near DOCK8 is identified by the 
combination of CM and nevus count (Table 1, rs478882 and rs520015 r2EUR=0.96)10. The third locus
is the previously-reported region on chromosome 16 containing FTO with SNP rs62034139 meeting
our significance requirements (Pmeta_r=3.7×10-8, I2=36.8). 
A role for multiple pathways in the development of CM
While interpretation of the variants and genes associated with new CM loci require further 
laboratory analyses to confirm biological relationships, they nonetheless offer clues suggesting 
multiple pathways are involved in CM risk. For example, a region on chromosome 17 spanning the 
3′ UTR of TP53 implicates the tumor suppressor TP53, with peak SNP rs78378222 (Table 2) also 
associated with nevus count (Supplementary Table 9). The rs78378222 TP53 variant has no high-
LD (r2EUR>0.6) proxy variants, and rs78378222 itself has been shown to disrupt the polyadenylation 
signal sequence from AATAAA to AATACA, impairing proper 3′ termination and polyadenylation 
of the TP53 transcript and resulting in reduced mRNA expression levels11. Associations with 
rs78378222 have been observed for basal cell carcinoma (BCC)11,12 and glioma13,14. We also 
identified an independent additional CM associated variant at the TP53 locus, rs1641548 
(Supplementary Table 3; OR=1.08, Pmeta=1.1×10-9), which has not been reported as associated 
with other traits.
Two new CM loci hint at a potential role for immunity in the etiology of melanoma. Specifically, 
rs28986343 in the HLA region was found to be associated with CM (OR=1.15, Pmeta=1.6×10-8; 
Table 2). Interestingly, two variants in the HLA region, rs9275642 and rs1050529, have previously 
been associated with BCC12; the CM variant rs28986343 is independent of both of these BCC 
variants (r2EUR<0.03). In addition, the rs6908626 variant on chromosome 6 (Table 2) is in strong LD
(r2EUR=0.97) with SNPs (e.g., rs72928038) associated with autoimmune disorders including 
vitiligo15, suggesting a potential role of this locus in immunity. While we did not observe significant
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eQTLs or TWAS results for this locus in skin-related tissues, rs6908626 is near BACH2, a gene that
plays a critical role in immune regulation16, as well as CASP8AP2, a component of the death-
inducing signaling complex involved in Fas-mediated apoptosis17. Evidence at this stage for an 
immune-related germline genetic pathway is suggestive, but deserves further study.
Consistent with prior studies implicating genes and loci associated with telomere maintenance in 
both melanoma families18-20 as well as in population-based studies of sporadic melanoma21-23, we 
identified four telomere length-associated variants as novel genome-wide significant CM loci 
(Table 1-2, Supplementary Table 5). Three loci previously reported as marginal CM 
associations23 were found here to be genome-wide significant (rs3950296 near TERC, OR=1.08, 
Pmeta=4.5×10-11; rs143190905 near RTEL1, OR=1.15, Pmeta=6.5×10-13; rs4731207 near POT1, 
OR=0.93, Pmeta=2.2×10-15), and one additional novel association was observed for rs2967383 near 
MPHOSPH6 (OR=1.07, Pmeta=2.2×10-9). Of these, allelic gene expression is supported by TWAS 
findings for MPHOSPH6 in both sun-exposed and non-sun-exposed skin, as well as additionally for
OBFC1 at another known genome-wide significant locus in transformed dermal fibroblasts. Lastly, 
in addition to a previously-identified signal at the telomerase reverse transcriptase (TERT) multi-
cancer risk locus on chromosome 5 (rs13178866, Pmeta=1.1×10-43), conditional and joint analysis 
using GCTA identified two independent genome-wide significant CM associations at this locus 
(rs7705526, Pmeta=2.0×10-14; rs2853667, Pmeta=7.7×10-9).
We identified multiple loci that potentially implicate genes established to regulate the development 
and differentiation of cells of melanocytic lineage as also having a role in CM. A new locus on 
chromosome band 1p31.3 with lead SNP rs670318 is located approximately 50kb from a key 
regulator of neural crest development, FOXD3. While eQTL analysis did not identify associations 
between this variant and expression of any nearby genes in melanocytes or other skin tissues, 
FOXD3 is known to be downregulated during melanocyte development and is poorly expressed in 
differentiated cultured melanocytes. Melanocyte TWAS identified the expression of NOTCH2,  a 
gene that plays a role in the maintenance and differentiation of melanocytes24, as significantly 
associated with CM. Higher melanocyte-specific expression of NOTCH2 is associated with the CM 
risk allele. 
TWAS analysis using melanocyte-specific expression (Supplementary Table 10) of the 
chromosome 16 locus with lead SNP rs4420522 (Table 2, OR=0.93, Pmeta=8.3×10-14) implicates the 
following target genes: CDH1, ZFP90, FTLP14, and TANGO6. Among these, CDH1 has a well-
characterized role in progression of melanoma and other cancer types. CDH1, a calcium-dependent 
protein that regulates cell adhesion and motility, is considered the major adhesion molecule between
melanocytes and keratinocytes25, with expression of CDH1 frequently lost during progression from 
radial to vertical melanoma growth26. The risk allele of the lead CM SNP, rs4420522, is associated 
with higher levels of melanocyte CDH1 expression and is also in strong LD (r2EUR=0.93) with 
rs9929218, which is a GWAS hit for colorectal cancer27.
eQTL colocalization analyses
In order to annotate CM GWAS loci for candidate susceptibility genes for pathway analyses as well
as future functional studies, we turned to eQTL colocalization analyses in addition to the TWAS 
data. Colocalization analyses of genome-wide significant CM GWAS loci and eQTLs from four 
skin-related tissues using eCAVIAR28 nominated 35 genes from 19 CM GWAS loci with a 
colocalization posterior probability (CLPP) cutoff of 1% (Supplementary Table 15). Considering 
only melanocyte eQTLs, 11 genes with colocalizing eQTLs were identified at 9 loci. We then 
combined the 105 unique genes nominated by colocalization and TWAS analyses as a set of 
candidate susceptibility genes for pathway enrichment analysis using the Ingenuity Pathway 
Analysis (IPA) tool. Among significantly enriched canonical pathways were those relevant to 
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melanin biosynthesis, melanocyte development, as well as epithelial adherens junction signaling 
(Supplementary Table 16). Amongst the top upstream regulators of candidate melanoma 
susceptibility genes was TFEB, a member of the microphthalmia family of basic helix-loop-helix– 
leucine-zipper (bHLH-Zip) transcription factors (Supplementary Table 17; P = 4.6 x 10-4). 
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Supplementary Figures
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Supplementary Figure 1: Quantile-Quantile plots. 
Quantile-quantile plots of negative log10 two-sided P-value derived from a logistic regression 
GWAS for all post QC imputed SNPs with a MAF > 0.005. The sample size for each GWAS is 
listed in Supplementary Table 1 and analysis methods for each GWAS are in the Online 
Methods. A: AMFS; B: CIDR_WAMHS; C: EPIGENE; D: GenoMEL_P1; E: GenoMEL_P2; F: 
HARVARD; G: HEIDELBERG; H: MDACC; I: MELARISK; J: MIA_PAH; K: QMEGA_610k; 
L: QMEGA_omni; M: UKBB500K_pathconf; N: GSEdinCIDRchr; O: italy; P: greek; Q: spain; R: 
PLCO; S: MICHIGAN; T: QSkin; U: BNMS; V: 23andMe; W: UKBB500K_selfrep. 
11
12
13
14
Supplementary Figure 2: Effect size estimates across contributing GWAS.
Forest plots showing results across the studies for the most significant SNP at each of the 54 
genome-wide significant loci. Results shown for meta-analysis with only clinically-confirmed cases
(“overall_conf”) and including self-reported cases (“overall”). Estimated log(OR) and 95% 
confidence intervals are plotted. The results for each study were calculated using the sample sizes 
listed in Supplementary Table 1.
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Supplementary Figure 3: Effect size and minor allele frequency by geographic region.
Forest plots showing the effect size estimates, 95% confidence intervals and allele frequency for 
each independent genome-wide significant SNP grouped by geographic region (AU: Australia, 
7398 cases and 13413 controls; NE: Northern European; 13498 cases and 26808 controls; SE: 
Southern European, 6445 cases and 7819 controls; US: United States, 3710 cases and 32825 
controls). Allele frequency is indicated by point size.
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Supplementary Table Legends
Supplementary Table 1. Summary of GWAS sets.
Type is clinically confirmed cutaneous melanoma (CM) or self-report. Population is the broad 
population of origin for samples. European is multiple European countries; US United States, UK 
United Kingdom; European-derived is combined populations drawn from Australian and 
European countries. MIA_PAH includes Australian case and control samples supplemented with 
additional UK controls. The Brisbane Nevus Morphology Study (BNMS) includes a combined set 
of Australian and German cases and controls. Principal component analysis was used to ensure 
homogeneity within GWAS; see GWAS descriptions for details. Study is the GWAS name. In 
addition to case and control number, the effective case and control number to better display 
discovery power was calculated as 
2/σ 2, where σ
2
=√( (1/CaseN )+(1/ControlN))
GWAS Array is the array used for genotyping. When arrays were combined SNPs were filtered to 
the minimum overlapping set (see Methods). The Harvard, BNMS, and 23andMe GWAS were 
imputed to 1000 genomes phase 1 v3; all other data sets were imputed to HRC v1.1 using the 
Michigan Imputation Server. The genomic inflation (Lambda) and LD Score Regression (LDSC) 
Intercept and its standard error (SE) 1 are both reported as the intercept better reflects test statistic 
inflation while lambda is also influenced by true polygenic signal and sample size.
The field “In previous meta-analyses?” indicates if a GWAS was included in 8. *This GWAS was 
included in the previous meta-analysis, but has now been supplemented with additional cases and 
controls such that 39% of cases and 92% of controls are new.
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Supplementary Table 2. Inflation, LD Score intercept and genetic correlation between 
confirmed and self-report sets.
Dataset is the confirmed meta-analysis, the total confirmed plus self-report (Confirmed plus SR), 
the UK Biobank self-report GWAS (UK Biobank SR), and the 23andMe self-report set. Array 
heritability (h2), genomic inflation factor (Lambda), LDSC intercept and its SE, and the ratio 
between them are reported 1. The genetic correlation (Rg) and its SE as calculated by LDSC indicate
a high degree of genetic overlap between self-report and confirmed GWAS datasets.
20
Supplementary Table 3. Annotation and detailed results for independent SNPs associated 
with CM in the total confirmed plus self-report meta-analysis.
Locus: Independent SNP within 1 MB are combined into a single locus. SNP: Independent SNP 
number. CHR and BP are provided as per hg 19 positions. rsID: dbSNP142 rs number. 
We list the Nearest gene and Nearest protein coding genes as reported by the open targets 
genetics platform 29. Where loci overlap, we summarise the TWAS results using melanocyte-
specific expression (Online Methods, Supplementary Table 11) or gene expression from the skin 
representing sun-exposed skin, non-sun-exposed skin, and transformed skin fibroblasts from GTEx 
(Online Methods, Supplementary Table 12). If known we list the functional gene target based on 
presence of a missense protein change, or if identified by a previous publication the gene name and 
PUBMED ID. 
CHR:BP:REFALT is a positional ID made by combining HRC position, ref and alt allele. Effect 
allele (EA) and non-effect allele (NEA) as well as the freq of the effect allele (EA freq) are 
provided.  For the two inverse variance weighted meta-analysis of log(OR) effect-sizes (derived 
from the logistic regression GWAS reported in Supplementary Table 1)  performed using PLINK 
v1.9 30 - the total (confirmed and self-report combined), and the confirmed cases only - we report 
summary data including number of contributing GWAS (N), Fixed effects two-sided P-value and 
OR (Pmeta, OR) and random effects (Pmeta_r, OR random), and measures of heterogeneity (Q 
and I2).  Finally, we report the per study OR for the EA allele for each study. To account for 
multiple testing only SNPs reaching genome-wide significance (P<5×10-8) are reported; see Online 
Methods for additional filters on significant loci.
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Supplementary Table 4. SNPs independently associated with CM in the total analysis set.
The total inverse-variance weighted CM meta-analysis includes all confirmed and self-report cases, 
with a sample size of 36,760 melanoma cases and 375,188 controls.
Locus: Independent SNP within 1 MB are combined into a single locus. SNP: Independent SNP 
number. CHR and BP are provided as per hg 19 positions. rsID: dbSNP142 rs number. 
CHR:BP:REFALT is a positional ID made by combining HRC position, ref and alt allele. Effect 
allele (EA) and non-effect allele (NEA) as well as the freq of the effect allele (EA freq) are 
provided. BETA is the log of the fixed effects OR for the total (confirmed plus self-report) meta-
analysis and its standard error (SE) and P-value (Pmeta).
Conditionally independent SNPs were determined using a stepwise model selection as implemented
in GCTA31,32 (Online Methods) with the resultant adjust joint conditional BETA, SE and P-value 
reported. Finally, we report the linkage disequilibrium r as estimated in the reference population for 
SNP i and SNP i + 1 (Ld_r). This can be informative when the joint conditional P is more 
significant than the single SNP analysis (e.g., where two adjacent SNPs are in negative LD).
To limit the chance of false positive claims of novel SNP/loci, we further filtered the list of 75 
conditionally independent variants to those (i) genome-wide significant (P < 5 × 10-8) in single SNP 
and joint conditional analysis, and (ii) as recommended 33 where there was evidence of 
heterogeneity between studies (I2 > 31%) the random effect P-value also needed to be < 5 × 10-8. 
The Independent SNP field reports this; if a variant passes all filters its number is recorded; 
otherwise the reason for filtering is noted; het indicates the SNP has I2 > 31% and the random 
effects is not significant; cojo indicates the variant is only significant in the cojo analysis and not p 
5 × 10-8 in the initial single SNP GWAS so is not counted as a secondary SNP at this locus.
aWhile the lead SNP selected by joint analysis rs12523094 has meta-analysis I2 > 31 and a random 
effects p-value < 5 × 10-8 there are SNPs in LD that pass this filter.  E.g., rs12173258 has the 
strongest p-value and is passes filters (Pmeta = 1.1 × 10-11 and I2 =29.6) and this locus was retained. 
bThe HLA region is excluded from LD reference panel used for conditional analysis (See Online 
Methods) and the lead SNP is reported. cAll SNPs at this locus near the FTO gene, including the 
lead SNP, have I2 > 31 and a random effects p-value < 5 × 10-8, and as such is not counted as an 
independent CM risk locus in this analysis.
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Supplementary Table 5. Independent CM SNPs and their association with risk phenotypes.
Locus: Independent SNPs within 1 MB are combined into a single locus. SNP: Independent SNP 
number. CHR and BP are provided as per hg 19 positions. rsID: dbSNP142 rs number. Nearest, or 
if known likely functional gene target, is provided. The meta-analysis P-value for the confirmed 
only sets (Pmeta confirmed) and total including self-report (Pmeta confirmed SR) are listed for 
each variant, as is their their association P-value from a series of GWAS of melanoma risk 
phenotypes from the UK Biobank (Online Methods); Ease of tanning (P Ease), Number of 
Childhood sunburns (P Childhood Sunburns), Skin Colour, non-red hair colour (Hair Colour) as
well as red hair yes/no (Red Hair). Each SNP’s association with leukocyte telomere length (P 
Telomere Length) taken from a GWAS of 37,684 individuals 34 and the same nevus count GWAS 
meta-analysis used for the joint analyses of CM and nevus count and pigmentation (N = 65,597, 
Methods). Two-sided P-values from logistic (binary traits) or linear (quantitative) regression 
GWAS are reported for the listed traits.
For a number of SNPs, telomere GWAS results were not available for the lead CM SNP; where 
possible a proxy SNP (Telomere SNP) was identified using an expanding LD window in PLINK 
v1.9 using the same LD reference panel as the GCTA conditional analysis (Online Methods). The 
LD window to search for proxies started at 2mb and 100 SNPs wide, with a minimum LD r2EUR > 
0.9, with the threshold relaxed until a SNP was identified; if no SNP was found with a window of 
1000 SNPs, 4 Mb and LD r2EUR > 0.5 the search was stopped.  LD r2 between the Telomere SNP 
and the lead SNP is listed (r2) 
aFor two SNPs, rs7705526 and rs143190905 data for telomere association was not available for the 
lead SNP nor a proxy with LD r2EUR > 0.5. For these two SNPs the p-value is derived from a 
separate telomere GWAS 35  identified via the open targets genetic platform. bSNP is not in the 
Nevus GWAS meta-analysis data, nor is there a proxy SNP within a window of 1000 SNPs, 4 Mb 
and LD r2EUR > 0.5. cP value for a proxy SNP for rs116927526 is reported; rs193247693 LD r2EUR 
0.70 
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Supplementary Table 6. SNPs independently associated with CM in the confirmed cases only 
analysis set.
Locus: Independent SNPs from the confirmed cases meta-analysis within 1 MB are combined into a
single locus. SNP: Independent SNP number. SNP formally significant and independent 
discounts SNPs that, while selected in the joint conditional analysis (Online Methods), are not 
significant in the single SNP GWAS (e.g. Pmeta > 5 × 10-8 or Pmeta_r > 5 × 10-8 where heterogeneity I2 
> 31). See footnotes below for further detail. 
CHR and BP are provided as per hg 19 positions. rsID: dbSNP142 rs number. CHR:BP:REFALT
is a positional ID made by combining HRC position, ref and alt allele. Effect allele (EA) and non-
effect allele (NEA) as well as the freq of the effect allele (EA freq) are provided. BETA is the log 
of the fixed effects OR for the confirmed cases only meta-analysis and its standard error (SE) and 
P-value (Pmeta). Conditionally independent SNPs were determined using a stepwise model 
selection as implemented in GCTA (Online Methods) with the resultant adjust joint conditional 
BETA, SE and P-value reported. Finally, we report the linkage disequilibrium r as estimated in the 
reference population for SNP i and SNP i + 1 (Ld_r). This can be informative when the joint 
conditional P is more significant than the single SNP analysis (e.g. where two adjacent SNPs are in 
negative LD). 
For reference we append the relevant summary data including number of contributing GWAS (N), 
Fixed effects P-value and OR (Pmeta, OR) and random effects (Pmeta_r, OR random), and 
measures of heterogeneity (Q and I2) from the confirmed cases only meta-analysis results 
performed using  PLINK v1.930.  
We also report the per study OR for the EA allele for each study. 
Results are compared to the “Total Meta-analysis lead SNP” with the overlapping locus number 
from Supplementary Table 3 provided.
aWhile the lead SNP in this locus selected by conditional analysis has fixed P > 5 × 10-8, I2 
heterogeneity measure > 31% and a random meta-analysis P-value > 5 × 10-8, other SNPs exist that 
qualify, e.g. chromosome 2 rs3769823 r2EUR = 0.75 with lead SNP rs10931936;  chromosome 5 
rs12173258 r2EUR = 0.82 with lead SNP rs11747245; chromosome 8 rs1481853 (r2EUR = 0.99 with 
lead SNP rs13263376); chromosome 12 rs4257028 (r2EUR = 0.99 with lead SNP rs4763456); 
chromosome 16 rs16953002 (r2EUR = 0.85 with lead SNP rs62034139); chromosome 16 rs2967361 
(r2EUR 0.85 with lead SNP rs2911423). bWhile the lead SNP in the total meta-analysis is rs2301293, 
that SNP is P > 5e-8 in the total meta-analysis and not formally a CM locus. cI2 heterogeneity 
measure > 31% and a random meta-analysis P-value > 5 × 10-8. dIndicates the variant is only 
significant in the cojo analysis and not p=5 × 10-8 in the initial single SNP GWAS, so is not counted 
as a secondary SNP at this locus.
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Supplementary Table 7. Results from total confirmed plus self-report meta-analysis for SNPs 
with meta-analysis P < 5 x 10-8.
Fixed or random effects meta-analysis results are displayed with respect to I2 < 31% (Online 
Methods). The meta-analysis was an inverse-variance weighted meta-analysis of log(OR) effect-
sizes derived from the logistic regression GWAS for all GWAS listed in Supplementary Table 1 
(36,760 melanoma cases and 375,188 controls). All p-values are two-sided.
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Supplementary Table 8. Sample sizes for sub phenotype GWAS analysis.
Numbers of cases and controls available across contributing GWAS data for the histology, age and 
sex stratified GWAS analyses.
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Supplementary Table 9. Combined analysis of CM and Nevus count GWAS meta-analyses.
Total sample size for the total CM meta-analysis includes all confirmed and self-report cases, with a
total sample size of 36,760 melanoma cases and 375,188 controls. The Nevus GWAS meta-analysis
included 65,597 participants. Two-sided P-values from each meta-analysis was were 
combined using Stouffer’s method (see Methods). 
LD calculations performed in PLINK using a reference panel of 10,000 white British UK Biobank 
individuals as implemented in the FUMA platform was used to identify independent SNPs with P < 
5 × 10-8; independent SNPs within 1 Mb were considered to be single loci (Online Methods). The 
lead SNP for each locus is reported. Bolding indicates that the locus is significant at a Bonferroni 
corrected P-value threshold of P ≤ 1.25 × 10-8. Chromosome (CHR), base pair (BP) and rsID are 
provided for the peak variant for each locus using hg19 positions. Effect allele (EA) and non-effect 
allele (NEA) as well as the freq of the effect allele (EA freq) are provided. We list the Nearest 
gene and Nearest protein coding genes as reported by the open targets genetics platform29.  If the 
lead SNP is an eQTL for skin tissues in GTEx we list the gene (GTEX skin eQTL gene); if the p-
value is not significant following Bonferroni correction ( > 0.05 divided by the number of genes) 
the actual P-value is also reported. If known we list the functional gene target based on presence of 
a missense protein change, or if identified by a previous publication the gene name and PUBMED 
ID. 
If the locus overlaps with a locus identified in the total confirmed plus self-report CM meta-analysis
(Table 1, Table 2, Supplementary Table 3) its number is noted here, as is the peak CM rsID if 
appropriate, and the LD r2EUR between the two SNPs (Overlapping CM locus, rsID and LD r2 
between lead SNPs). 
If the locus overlaps with a recent combined analysis of CM and nevus count GWAS meta-analysis
10 this is noted (otherwise novel ones are indicated by new), and the peak SNP there is provided, as 
is the LD r2EUR between the new peak and that SNP, as well as the likely model for this locus (CM 
alone, Nevus alone, or pleiotropic for CM and nevus count (Overlapping 2018 Nevus+CM locus; 
rsID, LD r2 between lead SNPs, and 2018 Model). 
The Model field indicates which GWAS-PW model has a PPA > 0.5 (Online Methods); model 3, 
pleiotropic for CM and Nevus count (CM+Nevus) or Model 1 (CM alone). No loci were associated 
with model 2, Nevus count alone. Where appropriate we also indicate is this locus is pleiotropically 
associated with pigmentation (Online Methods, Supplementary Table 10).
We summarise the stouffer’s method meta-analysis and GWAS-PW approach (Online methods). 
For the peak locus SNP in field rsID we provide the Z score and it variance (V) for the total CM 
GWAS meta-analysis (CM), the Nevus GWAS meta-analysis (Nevus). The P-value from Stouffer 
meta-analysis of both (CM + Nevus P). GWAS-PW assigns SNPs to LD blocks, and the hg19 start 
and end bp for each is provided as well as the maximum Z score for CM or Nevus for SNPs within 
each block. The PPA for GWAS-PW models for the association signal at each block being CM 
alone, Nevus alone, or CM + Nevus are provided. GWAS-PW also reports a 4th model, where the 
signal is co-located but independant. This is unlikely for nevus count and melanoma, where nevus 
count is a direct risk for melanoma 10 and as such all model 4 PPAs were dropped and scores for the 
remaining 3 models reweighted to sum to 1. As all PPA values for model 4 were all < 0.01 barring 
locus 41, peak SNP rs9651783 on chromosome 11 which reach 0.03, again supporting that 
colocation is an unlikely model for CM and nevus count, this made little different to the final model
PPA.
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Supplementary Table 10. Combined analysis of CM and hair colour GWAS.
Total sample size for the total CM meta-analysis includes all confirmed and self-report cases, with a
total sample size of 36,760 melanoma cases and 375,188 controls. The hair colour GWAS included 
352,662 UK Biobank participants. Two-sided P-values from each meta-analysis were 
combined using Stouffer’s method (see Methods). 
The independent locus, as defined by LD calculations implemented in FUMA platform (Online 
Methods), that is novel to previous reports and has a GWAS-PW model 3, pleiotropy, PPA > 0.5 is 
reported (CM + Hair colour Locus; Supplementary Methods). Bolding indicates that the locus is 
significant at a Bonferroni corrected P-value threshold of P ≤ 1.25 × 10-8. Chromosome (CHR), 
base pair (BP) and rsID are provided for the peak variant for each locus using hg19 positions. 
Effect allele (EA) and non-effect allele (NEA) as well as the freq of the effect allele (EA freq) are 
provided. [For the peak locus SNP in field rsID we provide the nearest gene and nearest protein 
coding gene.].  If the lead SNP is an eQTL for skin tissues in GTEx we list the gene (GTEX skin 
eQTL gene); if the p-value is not significant following Bonferroni correction ( > 0.05 divided by 
the number of genes), the actual P-value is also reported. If known, we list the functional gene 
target based on the presence of a missense protein change, or if identified by a previous publication,
the gene name and PUBMED ID. 
 
If the Locus overlaps with a locus identified in the total confirmed plus self-report CM meta-
analysis (Table 1, Table 2, Supplementary Table 3) its number is noted here (CM Locus), as is 
the peak CM rsID if appropriate, and the LD r2EUR (LD_r2) between the two SNPs.
The Model field indicates which GWAS-PW model has a PPA > 0.5 (Online Methods); model 3, 
pleiotropic for CM and Pigmentation (CM+Pigment) or Model 1 (CM alone). Where appropriate we
also indicate is this locus is pleiotropically associated with nevus count (Online Methods, 
Supplementary Table 9).
 
For the peak locus SNP in field rsID we provide the Z score (Z) and its variance (V) for the total 
CM GWAS meta-analysis (CM), the Hair colour GWAS (Hair), and the P-value from Stouffer 
meta-analysis of both (CM + Hair P). GWAS-PW assigns SNPs to LD blocks (50 SNPs wide) and
provides the maximum absolute Z score for CM or Hair colour for SNPs within each block. The 
PPA for GWAS-PW models for the association signal at each block (PPA) being CM alone, hair 
colour alone, or CM + hair colour are provided.
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Supplementary Table 11. Top melanoma TWAS genes using melanocyte eQTL data as a 
reference.
For genes whose expression in melanocytes is predicted to be significantly associated with CM by 
TWAS (Online Methods; melanocyte eQTL dataset from 106 individuals), the transcript gene 
name (Gene) along with its hg19 chromosome (CHR), transcription start (Start) and end (End) 
positions are reported. We also provide the peak CM SNP’s rsID (CM rsID) and Z score for 
association with CM in the total (confirmed plus self-report) meta-analysis (CM Z). In addition, we
report the rsID of the most significant eQTL variant in the locus from the 1000 genomes reference 
panel for the named transcript (eQTL Top Variant), that variant’s eQTL Z score (eQTL Z), and 
that variant’s total GWAS meta-analysis Z-score (CM Z for eQTL variant). The number of 
variants included in the TWAS models for each locus is reported (Number of variants), as is the 
weighted number of variants (Number of Weight). For each transcript the best performing TWAS 
Model, and its TWAS Z and TWAS P are provided (See Online Methods for the statistical tests). 
We also provide TWAS P cutoff that we applied based on the multiple testing corrections 
described in Online Methods. To assist interpretation, we note if the significant gene maps to a 
previously or newly identified CM locus, and if so, report the peak SNP and locus number from 
Supplementary Table 3 or is otherwise new to CM. As done for independent SNPs identified in 
the total and confirmed CM meta-analysis, TWAS genes identified within 1 Mb of each other were 
combined in a single locus. Finally, we report if this same transcript was significantly associated 
with CM in Zhang and colleagues’ work36, which applied melanocyte TWAS to the phase 1 CM 
data (Reported by Zhang; Y=yes, N=no). 
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Supplementary Table 12. Top melanoma TWAS genes using skin eQTL data as a reference.
For genes whose expression in three skin tissues (sun-exposed, not-sun-exposed, and fibroblasts) 
within GTEx (V7) is predicted to be significantly associated with CM by TWAS (Online 
Methods), the transcript gene name (Gene) along with its hg19 chromosome (CHR), transcription 
start (Start) and end (End) positions are reported. We also provide the peak CM SNP’s rsID (CM 
rsID) and Z score for association with CM in the total (confirmed plus self-report) meta-analysis 
(CM Z). In addition we report the rsID of the most significant eQTL variant in the locus from the 
1000 genomes reference panel for the named transcript (eQTL Top Variant), that variant’s eQTL 
Z score (eQTL Z), and that variant’s total GWAS meta-analysis Z-score (CM Z for eQTL 
variant). The number of variants included in the TWAS models for this locus are reported 
(Number of Variants), as is the weighted number of variants (Number of Weight). For each 
transcript the best performing TWAS Model, and its TWAS Z and TWAS P are provided (See 
Online Methods for the statistical tests). We also provide TWAS P cutoff that we applied based on
the multiple testing corrections described in Online Methods. To assist interpretation, we note if 
the significant gene maps to a previously or newly identified CM locus, and if so, report the peak 
SNP and locus number from Supplementary Table 3 or is otherwise new to CM. As done for 
independent SNPs identified in the total and confirmed CM meta-analysis, TWAS identified genes 
within 1 Mb of each other were combined in a single locus. 
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Supplementary Table 13. Top melanoma TWAS genes using all tissues eQTL data as a 
reference.
For genes whose expression in 45 GTEx (V7) tissues (excluding 3 skin tissues shown in 
Supplementary Table 12) is predicted to be significantly associated with CM by TWAS (Online 
Methods), the transcript gene name (Gene) along with its hg19 chromosome (CHR), transcription 
start (Start) and end (End) positions are reported. We also provide the peak CM SNP’s rsID (CM 
rsID) and Z score for association with CM in the total (confirmed plus self-report) meta-analysis 
(CM Z). In addition, we report the rsID of the most significant eQTL variant in the locus from the 
1000 genomes reference panel for the named transcript (eQTL Top Variant), that variant’s eQTL 
Z score (eQTL Z), and that variant’s total GWAS meta-analysis Z-score (CM Z for eQTL 
variant). The number of variants included in the TWAS models for this locus are reported 
(Number of Variants), as is the weighted number of variants (Number of Weight). For each 
transcript the best performing TWAS Model, and its TWAS Z and TWAS P are provided (See 
Online Methods for the statistical tests). TWAS P cutoff was set for each tissue based on the 
number of genes passing a heritability cutoff and being tested within each tissue type (0.05/number 
of genes). P-values of genes that pass a Bonferroni-corrected cross-tissue wide P-value cutoff 
(based on the total number of tested genes in 45 tissues, N=211,941) are bolded. To assist 
interpretation, we note if the significant gene maps to a previously identified CM locus, and report 
the applicable peak SNP and locus number from Supplementary Table 3.
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Supplementary Table 14: Tabulation of loci associated across primary and secondary 
analyses
Sample size: The Total CM inverse variance weighted meta-analysis of logistic regression GWAS 
included 36,760 melanoma cases and 375,188 controls. The nevus GWAS meta-analysis included 
65,597 participants. The hair colour GWAS included 352,662 UK Biobank participants. Two-
sided P-values from the CM meta-analysis, and either the nevus or hair colour GWAS, 
were combined using Stouffer’s method (see Online Methods). For TWAS, summary 
statistics from Total CM GWAS meta-analysis and eQTL datasets of different sample sizes
were used (GTEx v7 datasets; n = 106 for melanocytes; See Online Methods for the 
statistical tests). 
Loci derived from the Total CM meta-analysis were significant at multiple testing corrected 
threshold of P<5×10-8; the significance threshold for the additional, secondary analyses were further
correct to P<1.25×10-8 (see Online Methods).
Each Locus is numbered in order (see Online Methods for how loci are defined), and the positions 
(CHR, BP) and rsID for the lead SNP are reported for the SNP with the strongest total CM 
associations signal (totalCM, TWAS results) or for the loci derived from the joint analysis, the SNP 
with the strongest joint p-value. Gene prioritises the functional target if known, followed by 
melanocyte or skin tissue TWAS data, or finally the closest protein coding gene (Supplementary 
Table 3, 11, and 12). For each of the named analyses we indicate with a “1” if the loci passes the 
significance threshold for that analysis (Supplementary Tables 3,9,10,11,12).
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Supplementary Table 15. Colocalization of melanoma GWAS signal and eQTLs from 
melanocytes and skin tissues.
eCAVIAR 28 was used for testing colocalization of melanocyte and GTEx skin tissue eQTLs (listed 
in eQTL dataset) for the reported gene (listed in Gene column), and the melanoma GWAS signal 
(here we report the CM GWAS locus, lead independent SNP). Fifty SNPs upstream of and 
downstream from the GWAS lead SNP in each locus were chosen to quantify the probability of the 
variant to be causal in both the GWAS and eQTL studies. 
We report the colocalization posterior probability (CLPP), which is the probability that the same 
variant is causal in both GWAS and eQTL (See Online Methods for the statistical tests). A cutoff 
of CLPP > 0.01 was applied to the resulting list of SNPs, and SNPs were further filtered using an 
LD r2 cutoff of > 0.9 with the GWAS lead SNP (1000 Genomes, EUR population), as well as to 
those with a significant eQTL P-value (<0.05/number of eGenes tested for each eQTL dataset). We 
report the SNP with the highest CLPP score for each gene, as well as its LD r2 with the lead 
GWAS SNP, and eQTL P-value. Finally, we indicate if the gene is also significantly associated 
with CM by TWAS in melanocyte or skin tissues (Supplementary Tables 11-12). 
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Supplementary Table 16. Enriched canonical pathways in genes identified through TWAS 
and colocalization from melanocyte or skin tissues.
All significant TWAS genes from melanocyte (Supplementary Table 11) plus skin tissues 
(Supplementary Table 12), as well as all colocalized genes identified by eCAVIAR applied to 
melanocyte and 3 skin tissue datasets (Supplementary Table 15) were queried as a gene list in IPA
analysis (Qiagen, version 46901286). Significantly enriched canonical pathways are displayed (-
log(P-value) > 1.3, right-tailed Fisher’s Exact Test). 
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Supplementary Table 17. Top 5 enriched upstream regulators in genes identified through 
TWAS and colocalization from melanocyte or skin tissues.
All significant TWAS genes from melanocyte (Supplementary Table 11) plus skin tissues 
(Supplementary Table 12), as well as all colocalized genes identified by eCAVIAR applied to 
melanocyte and all 3 skin tissue datasets (Supplementary Table 15) were queried as a gene list in 
IPA analysis (Qiagen, version 46901286). The top 5 enriched Upstream Regulators are listed (P-
value of overlap < 0.05, right-tailed Fisher’s Exact Test; Molecule Type and Target molecules in 
dataset are also reported).
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Supplementary Table 18: Results for UKBB self-report set for three loci no longer significant 
following their removal from the total meta-analysis
For each locus that is no longer significant following the exclusion of the UKBB self-report set we 
report the position and rsID for the lead SNP. For each SNP we report the results for the total 
inverse-variance weighted meta-analysis of log(OR) effect-sizes, which includes all pathology-
confirmed GWAS together with 23andMe and UKBB self-report cases (36,760 melanoma cases 
and 375,188 controls). We also report results for the meta-analysis without UKBB self-report cases 
(34,958 cases and 367,980 controls), and for logistic regression results for the UKBB self-report 
GWAS itself (1,802 self-report CM cases and 7,208 controls). For each GWAS we tabulate the 
respective log(OR) (BETA), standard error (SE) and P-value (P). All tests were two-sided and were
significant at a multiple testing corrected threshold of P<5×10-8.
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Supplementary Methods 
GWAS descriptions
Q-MEGA
1,617 CM cases were drawn from population-based studies undertaken in Queensland were 
combined as The Queensland study of Melanoma: Environment and Genetic Associations (Q-
MEGA) study 37. CM cases were histologically confirmed using the Queensland Cancer Registry 37. 
All contributing studies were approved by the Human Research Ethics Committees of QIMR 
Berghofer, University of Sydney, University of Melbourne and cancer registries of NSW, Victoria 
and Queensland. Informed consent was obtained from all participants.
Samples were genotyped in two phase using the Illumina HumanHap610 and Omni1-Quad arrays  
(San Diego, CA, USA), and to ensure maximum SNPs were retain each phase was cleaned, imputed
and analysed as QMEGA_610k and QMEGA_omni respectively.
Q-MEGA_610k: 926 Q-MEGA cases were combined with 1,799 unrelated controls genotyped on 
the Illumina HumanHap610  from the Brisbane Adolescent Twin Study 38,39. 20% of the samples 
were a singleton from twin pairs or sibling sets, with the remainder drawn from parents of twins. 
Controls were further supplemented by 2,155 endometriosis patients genotyped using the Illumina 
HumanHap670 array (San Diego, CA, USA) 40. Controls who self reported melanoma in themselves
or a family member were excluded. Following cleaning (see Online Methods) there were 912 cases
and 3,777 controls and 487,089 autosomal SNPs. Ethical approval is as per the overall Q-MEGA 
study above.
Q-MEGA_omni: 691 Q-MEGA CM samples were with 553 healthy cancer-free controls from the 
Study of Digestive Health (SDH) 41. After QC (Online Methods) there were 656 cases, 538 
controls and 767,979 SNPs available for imputation. Ethical approval is as per the overall Q-MEGA
study above.
AMFS
549 cases with histopathologically confirmed invasive CM, and 431 city, age and sex-matched 
controls from Melbourne, Brisbane, and Sydney, Australia were drawn from the Australian 
Melanoma Family Study (AMFS) 42. The outlined study was approved by the Human Research 
Ethics Committees of the University of Sydney, University of Melbourne and cancer registries of 
NSW, Victoria and Queensland. Informed consent was obtained from all participants. AMFS 
samples were genotyped using Illumina Omni1-Quad (San Diego, CA, USA) . After QC (see online
methods) there were 535 cases, 427 controls and 791,961 SNPs.
WAMHS
DNA samples were available from 1,289 CM cases from the Western Australian Melanoma Health 
Study (WAMHS) 43. The WAMHS population based study was collected from Perth, Australia 
based on  histopathology confirmed invasive, cutaneous melanoma cases in the Western Australian 
Cancer Registry. 
 
WAMHS CM cases were genotyped using Infinium HumanOmniExpressExome, and were 
combined with two control sets on matching arrays. The first was 960 Australian individuals 
(including healthy individuals, and a subset with ulcerative colitis) genotyped on the Infinium 
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HumanOmniExpressExome arrays from the Inflammatory Bowel disease (IBD) Clinical and 
Research Programme at the Royal Brisbane & Women’s Hospital Brisbane, Queensland 44. The 
second was 1,298 advanced glaucoma cases from the ANZRAG; Australian & New Zealand 
Registry of Advanced Glaucoma; 651 were genotyped on Omni1M and 647 on the 
HumanOmniExpress arrays from Illumina  (San Diego, CA, USA). Controls were not screened for 
melanoma. Following GWAS cleaning (Online methods),  including filtering to a common set of 
SNPs that passed QC across all arrays, 1,237 melanoma cases, 1,980 controls, and 567,914 SNPs 
were available for imputation.
 
This work was undertaken with ethics approval from The University of Western Australia and the 
Department of Health Western Australia, with ANZRAG inclusion approved  by the Southern 
Adelaide Clinical Human Research Ethics Committee. Informed consent was obtained from all 
participants.
UK Biobank
A full description of the UK Biobank dataset and the quality control and imputation approaches 
applied are described elsewhere 45. Briefly, UK Biobank is a volunteer cohort of approximately 
500,000 persons recruited between 2006 and 2010. Besides answering a broad range of questions, 
participants gave permission for their health records to be accessed and for linkage to national 
cancer registries which record pathologically and clinically diagnosed cancers; for melanoma 
essentially all diagnoses have pathological verification. The Cancer Registry records were searched 
for diagnoses made under ICD9 (172.x) or ICD10 (C43.x). Overall, 3,659 cases were identified 
with one or more diagnoses with the date of first diagnosis ranging from 1968 to 2015 at the time of
this analysis; about 40% of diagnoses were incident (following recruitment) while the remainder 
were made prior to recruitment into UK Biobank. UK Biobank participants also self-reported cancer
diagnoses at recruitment; overall 1,651 participants had a confirmed diagnosis of melanoma without
a self-report of melanoma (the majority of these confirmed diagnoses being after recruitment, the 
time at which self-reports were made), 1,873 reported melanoma but did not have a confirmed 
diagnosis and 2,008 had both a self-report of melanoma and a confirmed diagnosis.  
 
Within UK Biobank, biological samples were available for genetic analysis from 488,000 
participants. The majority of participants were genotyped using a purpose designed UK Biobank 
Applied Biosystems Axiom array assessing 826,000 SNPs and indels. The quality control and 
imputation approaches applied are described elsewhere 45. UK Biobank provides a lists of 
participants whose genetic results should be excluded on the basis of poor performance or close 
relatedness; these persons were excluded in our analysis. Non-European outliers were identified 
using the same approach that UK Biobank apply to their “Caucasian” definition: the ‘aberrant’ 
routine in R 46 was applied to PCs 1&2, 3&4 and 5&6, but anyone declaring themselves to be White
was included in this analysis (where UK Biobank automatically exclude “Irish” and “any other 
white background”); the lambda parameter used was 100.
 
Following the application of QC and restriction by ancestry as described above, we included 3,499 
individuals with confirmed melanoma from the cancer registry and a further 1,802 individuals with 
self-reported melanoma without cancer registry confirmation. The confirmed and self-reported 
cases were analysed separately, in a case-control analysis using four times as many controls as 
cases, randomly selected from UK Biobank.  
 
Analysis was conducted in PLINK2 correcting for population stratification by including PCs 1-15 
as covariates.
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Michigan
The Michigan Genomics Initiative (MGI) is a repository of patient electronic health and genetic 
data at Michigan Medicine 47.  MGI participants are recruited primarily through pre-surgical 
encounters at Michigan Medicine and consent to linking of genetic and clinical data for research 
purposes. Blood derived DNA was genotyped on Illumina Infinium CoreExome-24 bead arrays 
(San Diego, CA, USA). Genotype data was imputed to the Haplotype Reference Consortium using 
the Michigan Imputation Server, providing > 17 million imputed variants after standard quality 
control and filtering (minimac imputation R2 > 0.3). We restricted our analysis to samples of 
European descent based on Principal Component Analysis using the Human Genome Diversity 
Panel as references 48. The CM phenotype was derived from ICD-9 codes extracted from patient 
electronic health records using the PheWAS R package 49. We identified 1,198 CM cases samples 
required to have at least two inclusion ICD-9 codes for melanoma and 26,211 controls with zero 
inclusion or exclusion codes. The association analysis consisted of a Firth bias-reduced logistic 
regression controlling for sex, age and 10 principal components. The Firth test corrects for 
imbalance in case-control ratio 50 and was performed using the epacts software 
(https://github.com/statgen/EPACTS). All participants signed an informed consent form and the 
local Institutional Review Board approved the study.
GSXP1 & P2
GenoMEL Phase 1 and 2 are updated relative to previous reports 5,8 with CM samples from the 
Leeds melanoma cohort now included in the GSEdinCIDR dataset. For a more detailed description 
see 3,5, but briefly phase 1 includes cases with histologically confirmed CM from 7 collections 
centres from 5 European countries genotyped on the Illumina HumanHap300 BeadChip and 
HumanCNV370k arrays (San Diego, CA, USA). Controls were collected by the same groups as 
cases and were melanoma-free. After QC there were 1,075 cases and 2,163 controls. Phase 2 
samples includes cases and controls from 9 centres (4 new to phase 1) from 8 Europeans countries 
plus Israel, totalling 925 cases and 1,128 controls, with genotyping performed on the Illumina 
HumanHap610 array. All participants signed an informed consent form and the local Institutional 
Review Board approved the study.
GSEdinCIDR - Leeds/Cambridge/Scotland
Cases are from two sources. 2,949 are from several studies from Leeds and 1,379 from the 
Cambridge SEARCH study. Both were genotyped on the Illumina Infinium 
HumanOmniExpressExome (San Diego, CA, USA) array.
The Leeds data are predominantly from the Leeds melanoma cohort, a population-based melanoma 
study recruited population-based incident melanoma cases diagnosed between September 2000 and 
December 2012 from a geographically defined area of Yorkshire and the Northern region of the UK
3,51-53. Cases were identified by clinicians, pathology registers and via the Northern and Yorkshire 
Cancer Registry and Information Service to ensure overall ascertainment. For all but 18 months of 
the study period, recruitment was restricted to patients with Breslow thickness of at least 0.75mm. 
All controls and the first 960 cases recruited were examined by trained interviewers who performed 
a standardized examination of the skin, recording nevi by anatomical site and size.
CM cases were identified and recruited from the Eastern Cancer Registry and Information Centre 
(Eastern England) by the SEARCH study, University of Cambridge 54,55. CM cases were aged 18-70
at diagnosis. 5,304 of the controls are from Generation Scotland, sampled to preferentially select 
those individuals reporting English ancestry. 476 of the controls are from the Leeds Melanoma 
Cohort, selected to be matched by age and GP surgery to the cases. The Leeds controls were 
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selected to be melanoma-free while the Generation Scotland controls are simply population 
samples.
In Leeds participants consented to studies approved by the Northern and Yorkshire Research Ethics 
Committee. Approval for the SEARCH study was obtained from the Eastern Multicentre Research 
Ethics Committee, UK. Informed consent was obtained from all participants.
MDACC
The MDACC dataset consists of 931 white (non-Hispanic) individuals with cutaneous melanoma 
who were recruited together with 1,026 cancer-free controls (friends or acquaintances of patients 
reporting to other clinics at M.D. Anderson). Controls were frequency matched on age and sex. The 
The GWAS CM dataset also includes an additional 873 individuals presenting for treatment for 
cutaneous melanoma at M.D.Anderson. All samples were collected between March 1998 and 
August 2008. Samples were genotyped using the Illumina HumanOmni1-Quad_v1-0_B array (San 
Diego, CA, USA) and called using the BeadStudio algorithm. A more detailed description of the 
QC procedures applied to these data can be found elsewhere 4 The study protocols were approved 
by the Institutional Review Board at MD Anderson, and informed consent was obtained from all 
participants.
Harvard
410 pathologically confirmed invasive CM cases and 2,920 melanoma free controls were drawn  
from US non-Hispanic Caucasian participants of two cohorts; the Nurses’ Health Study and the 
Health Professionals Follow-up Study who were genotyped on Illumina HumanHap660 arrays (San 
Diego, CA, USA) 56). Cohort recruitment required informed consent, and ethical oversight and 
approval was via the Institutional Review Board at Brigham and Women's Hospital and the Harvard
School of Public Health. Following QC, imputation to 1000 genomes phase 1 Integrated Release 
Version 3 Haplotypes (2010-11 data freeze, 2012-03-14 haplotypes) was conducted using MACH
57,58. Only SNPs with a MAF > 0.01 were carried forward for analysis using logistic regression; age, 
sex, family history of melanoma and the first 5 principal components were included as covariates.
EPIGENE
787 CM cases genotyped on the Illumina CoreExome array (San Diego, CA, USA) were available 
from the EPIGENE cohort, which recruited histopathologically confirmed invasive CM cases (with 
informed consent) from southern Queensland, Australia 59. CM cases were aged 18-79 at the time of
diagnosis, and were diagnosed between April 1st 2007 and September 30, 2010. 
These were combined with 983 healthy controls from the Brisbane Adolescent Twin Study 38,39 
genotyped on the Illumina CoreExome array (San Diego, CA, USA); control samples were selected 
to be unrelated (PLINK IBD PI_HAT  < 0.1875) to each other, to EPIGENE samples, and to 
controls used in the QMEGA_610k GWAS. Following QC as performed for the other GWAS sets 
(Methods) there were 773 CM cases and 910 controls. Genotyped data was imputed to the HRC as 
outlined in the Online Methods. The study protocol was approved by the HREC of QIMR 
Berghofer Medical Research Institute, Brisbane, Australia. 
MIA_PAH
Clinically confirmed CM cases were were drawn from participants three cohorts genotyped on the 
Illumina Oncoarray (San Diego, CA, USA). Germline DNA samples and data from the Melanoma 
Institute of Australia (MIA) cohort (1,745 cases) were obtained from the MIA Biospecimen Bank 
(protocol HREC/10/RPAH/530), which is based on an Institute-wide prospective protocol of 
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registration and clinical data collection from all melanoma cases (MIA Melanoma Research 
Database, protocol HREC/11/RPAH/444). Study protocols for the MIA, as well as overall ethical 
oversight, was managed by the Sydney Local Health District (SLHD) Ethics Review Committee 
(RPAH Zone), Camperdown, New South Wales, Australia. All MIA cases were confirmed by 
histopathology. A further N = 236 were recruited from the Princess Alexandra Hospital and 
Brisbane treatment centres (PAH). Ethical approval for the PAH dataset was through the Metro 
South Hospital and Health Service, Human Research Ethics Committee, Woolloongabba, 
Queensland, Australia. All patients with melanoma recruited into the PAH study were diagnosed 
with locally invasive primary cutaneous melanoma and referred to the Multidisciplinary Melanoma 
Clinic at the Princess Alexandra Hospital and related clinics. Patients who proceeded to a sentinel 
lymph node biopsy procedure between 1994 and 2007 were considered for inclusion.  Patient 
demographics, date of diagnosis and clinicopathological characteristics of the primary melanoma 
for each patient were prospectively recorded in a hospital database through the PAH surgical clinic. 
Consenting patients were sent a saliva kit for DNA collection. The third set of samples was 
participants in the Q-MEGA cohort not previously genotyped an unrelated (IBD < 0.15) with 
participants in the Q-MEGA omni and Q-MEGA 610k GWAS (N = 60). 
Controls were cancer free women genotyped on the Illumina Oncoarray (San Diego, CA, USA) 60 
drawn from the population based controls of the Australian Ovarian Cancer Study (N = 1,134) 61,62, 
combined with N = 1,794 UK cancer free controls (all female) from the SEARCH study 63. PCA 
was used to confirm cancer free controls were homogenous with the Australian cases and controls.
GWAS samples were cleaned as per other datasets (Online Methods). In addition to the standard 
genotype QC (Online Methods) the Oncoarray genotype data was first cleaned and aligned as per 
Oncoarray Consortium protocols to remove poorly performing assays specific to that array 60. After 
QC and cleaning there were 1,933 CM cases (N = 1,641 from the MIA set, 232 from the PAH set , 
and 60 from Q-MEGA). 2,841 controls were available after cleaning (AOC N = 1,113, SEARCH = 
1,778).
MELARISK, France
Additional clinically confirmed CM cases and controls were available from two French cohorts 
contributing to GenoMEL Phase 1 and 2;  MELARISK (535 cases) 64 and the Supplementation in 
Vitamins and Mineral Antioxidants (SU.VI.MAX) study (856 controls - population samples not 
screened for melanoma) 65 34.  The project was approved by the  Human Research Ethics 
Committees of PARIS SAINT-LOUIS, PARIS NECKER and Ile de France II for the MELARISK 
study and from the Human Research Ethics Committee of PARIS Cochin for the SU.VI.MAX 
study. Informed consent was collected for all individuals taking part. Following genotyping on 
IHuman660W-Quad array (San Diego, CA, USA) at the Centre National de Genotypage (CNG, 
Evry, France), QC as per the Online Methods were applied. Post QC, 511 melanoma cases and 815 
controls were available for GWAS.
Essen-Heidelberg, Germany
Histologically confirmed CM cases (N = 1,218) were genotyped using the Illumina 
HumanCytoSNP-12v1-0_D arrays (San Diego, CA, USA). These were combined with healthy 
controls (N = 1,223) from Germany genotyped on the Illumina HumanOmniExpress12_v1_C array 
(San Diego, CA, USA). The combined genotyped data was thinned to the 220,000 SNPs  
overlapping across the arrays before applying the standard cleaning and quality control (Online 
Methods). Participation required informed consent, and the study was approved and overseen by the
Human Research Ethics Committee of University Hospital Essen.
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QSkin
Data for 17,695 individuals genotyped using the Illumina Global Screening Array (San Diego, CA, 
USA) was available from the QSkin cohort 66. Following excluding participants with > 5% genotype
missingness (n = 322), were related to another participant at PLINK IBD PI_HAT  > 0.1875 (N = 
400), or were more than 6 sd on PC1 and PC2 compared to a European reference population 
constructed using 1000 genomes data (N = 378; some individuals overlap across exclusions), 
16,708 participants were available. Genotyped SNPs were cleaned for GenTrain score <0.6, Hardy-
Weinberg P-value < 1 × 10-6, or a minor allele frequency (MAF) < 1%, leaving 496,695 SNPs for 
imputation. Imputation was performed using the University of Michigan Imputation Server as per 
the other GWAS datasets (Online Methods). Cleaned, imputed data were split into a CM GWAS set
(N = 1,285 with histopathologically confirmed CM and 2,493 controls without melanoma) and a 
distinct Nevus GWAS dataset (N = 12,930). The CM GWAS was performed using logistic 
regression in PLINK v1.9 with the first 10 principal components fitted as covariates.  The QSkin 
nevus phenotype was a self reported 4 point scale (None, some, a few, many based on a reference 
picture; see https://qskin.qimrberghofer.edu.au/page/About/Baseline_survey). Following rank 
normalisation in R. this was analysed using PLINK v1.9 as a quantitative phenotype with the 
orthoganol transformation of age, age2, sex, sex × age, and sex × age2 and the first 10 principal 
components fitted as covariates. Ethical approval and oversight of the QSkin project was managed 
by the Human Research Ethics Committee of QIMR Berghofer Medical Research Institute, 
Brisbane, Australia.
Brisbane Nevus Morphology Study
The ethical aspects of this research project have been given approval by the Human Research Ethics
Committee of Princess Alexandra Hospital and The University of Queensland. Patients and controls
for this study were all enrolled in the larger Brisbane Naevus Morphology Study, (BNMS) study 
run by University of Queensland Dermatology Research Centre. Recruitment of patients was via 
referral with patient consent from treating doctor (including private and public hospital clinics) or 
some patients had heard about the trial from friends or family and self referred. Controls were 
people with no history of melanoma who volunteered for the BNMS, often due to knowledge of it 
via friends, family, or who were being seen in the dermatology clinic and were offered 
participation. Once identified, participants are contacted by research assistants and asked if they 
would like to come for an in-person consultation and more information, and if they elect to proceed,
to complete the consent process.
Patients are asked to provide a saliva sample using a self-collection kit (Oragene-DNA self-
collection, DNA Genotec, Ottowa, ON, Canada).  A minimum of 2.5ug of DNA was provided to 
UQ Centre for Clinical Genomics (UQCCG) at the Translational Research Institute (TRI) for high 
throughput microarray processing. The concentration range for the submitted samples was 100 to 
300ng/ul, aliquoted in 96-well semi-skirted PCR Plates (Axygen Scientific) and sealed with Clear 
Self-Adhesive Topseal (PerkinElmer). These samples were genotyped on the Illumina Infinium 
Microarray on HumanCoreExome-24. 
To account for the family structure in the BNMS sample, dosage data was analysed using the 
Genome-Wide Efficient Mixed Model Association (GEMMA) algorithm67. The ordinary least 
squares beta output from GEMMA regression was converted to a log odds ratio a using a simplified
formula adapted from the first term of the formula provided by68 of B/(C(1-C)), where B is the 
ordinary least squares beta and C the proportion of cases.
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23andMe
Self-reported CM cases were defined as having answered yes, or reported melanoma for at least one
of the following question asked to 23andMe, Inc. participants 1) "Have you ever been diagnosed by 
a doctor with melanoma?"; 2) “What type(s) of cancer were you diagnosed with? Please check all 
that apply."; 3) "What type(s) of skin cancer did you have? Please check all that apply."; 4) "Have 
you ever been diagnosed with melanoma?"; 5) "Have you ever been diagnosed with or treated for 
any of the following conditions?” with the list including “Melanoma”. Cancer free controls were 
drawn from those who answered No, or not reporting melanoma, to any of the above questions, and 
without responding yes to any of these questions. Further, controls answered No to at least one 
general cancer questions, and Yes to none 1) "Have you ever been diagnosed with cancer, including
skin cancer or cancerous moles?"; 2) "Has a doctor ever told you that you have a type of cancer?"; 
3) "Have you ever been diagnosed or treated with any of the following conditions?  Cancer, any 
type”. 
DNA samples were genotyped using one of four genotyping platforms; two variants of the Illumina 
HumanHap550+ BeadChip  (V1, V2), a custom Illumina OmniExpress+ BeadChip (V3) with 
improved overlap with the V2 array, and a custom array (V4) designed for 23andMe, Inc. from 
Illumina that overlaps with the V2 and V3 arrays and improved coverage of lower frequency SNPs. 
Samples were filtered on < 98.5% call rate, < 97% European ancestry when compared to 1000 
genomes reference panels, or more closely related by IBD than first cousins. Genotyped SNPs were 
filtered for being non-polymorphic; failing parent offspring tests; HWE P < 1 × 10-20; genotype 
missingness >= 10% or exhibiting batch effects across the 4 GWAS arrays used. SNPs were 
imputed by genotyping batch (V1-V4), with 945446 SNPs passing QC across the batches. 
Following imputation to the September 2013 release of 1000 Genomes Phase1 reference panel 
using Minimac2, there were 12833621 SNPs in total with 9,829,439 exceeding imputation quality 
threshold (INFO) > 0.5. Variants in the HLA region, including imputed HLA alleles for HLA-A, B, 
C, DPB1, DQA1, DQB1, and DRB1 loci at four-digit resolution, were imputed using HIBAG6. 
Imputed HLA alleles were otherwise analysed as dosage data as per the rest of the imputed 
genotype data. Logistic regression using genotype dosages was performed with Age, sex and PC0-4
(first 5 Pcs) as covariates.
MelaNostrum Consortium:
Ethical approval was obtained from the National Cancer Institute, NIH and from each center listed 
below:
Athens – Andreas Sygros Hospital Study
The Athens sample is a case-control study that collected melanoma cases from Andreas Sygros 
Hospital and the Medical Oncology Center of Laiko Hospital. These are large referral centers for 
melanoma and skin cancer that receives the majority of melanoma cases in Athens and central 
Greece69. Melanoma cases were defined as individuals with a histologically confirmed diagnosis of 
invasive melanoma between 2000 to 2014. Melanoma-free controls were collected from blood 
donors of an Athens blood donation center or individuals with minor skin diseases and no history of
skin malignancy who attended the hospital outpatient service or who were hospital personnel. All 
participants were older than 18 years. Demographic variables, pigmentation traits (eye, hair, and 
skin color), skin phototype, tanning ability, and information from clinical examination were 
obtained through a questionnaire that was filled out by all participants under the supervision of a 
certified dermatologist who performed the clinical examination. The questionnaire and clinical 
examination was conducted for both melanoma cases and controls. The participation rate was 
approximately 95% for patients and 90% for controls. The study protocol was approved by the 
Scientific and Ethics Committee of Andreas Sygros Hospital, and all participating individuals gave 
written informed consent before study participation.
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Athens – Hellenic Cooperative Oncology Group (HeCOG)
Melanoma cases from this study were previously enrolled in Trial 13A/98, a prospective, 
multicenter, randomized phase III trial conducted at 13 institutions by the Hellenic Cooperative 
Oncology Group (HeCOG)70. The trial enrolled patients with histologically confirmed primary 
cutaneous melanoma between 1998 and 2004. Eligible cases were also required to be ≥18 years of 
age with an ECOG performance status ≤1, adequate organ function and no significant medical or 
psychiatric comorbidity. Cases were excluded if they had received prior adjuvant chemotherapy, 
radiotherapy or immunotherapy. Melanoma-free controls were randomly selected healthy unrelated 
Greek individuals. All participants gave informed consent to participate in the trial. This study was 
approved by the ethics committees of the Hellenic Cooperative Oncology Group, University 
Authorities and “G. Gennimatas” Hospital.
 
Barcelona – Melanoma: Image, Genetics and Immunology Study
The Melanoma Unit of from IDIBAPS (Barcelona, Spain), Hospital Clínic of Barcelona, and 
CIBERER (Instituto de Salud Carlos III, Spain) started recruiting familial and sporadic melanoma 
cases and controls in 1992. The collection consists of a series of case-series, case-control and cohort
studies from Barcelona, Spain 71-80. Since 1999, data has been collected on clinical information, 
follow-up, and biological species. Melanoma cases were defined as individuals with clinically 
diagnosed melanoma based on histopathological evaluation. Controls were cancer-free individuals, 
some of which were non-affected family members recruited for familial melanoma studies. In the 
case-control melanoma studies, the controls used have no personal or family history of melanoma. 
Matching was performed based on age and gender for some included studies. All participants 
signed an informed consent form and the local Institutional Review Board approved the study.
 
Cyprus
The Cypriot cohort consisted of 32 histologically confirmed unrelated cases of malignant melanoma
and 201 healthy controls. The control samples were cancer-free volunteers participating in the 
MASTOS study81. All subjects were above 18 years. All participants signed an informed consent 
form and the local Institutional Review Board approved the study.
Cesena
The Cesena study is a case-control study conducted at M. Bufalini Hospital, Cesena, Italy 82-87. 
Cases are cutaneous melanoma cases with histopathological confirmation which included 
hematoxylin and eosin staining, HMB-45, S100, and Melan-A (MART-1) makers. Healthy control 
subjects were recruited from patient’s spouses or friends from in-patients or out-patients at the 
dermatologic department mainly with diagnoses of streptodermitis, subcutaneous abscesses, 
lipomas, mild contact dermatititis, hair or nail diseases. Controls were melanoma free at time of 
recruitment and matched to cases on age, gender and region of birth. All participants donated a 
sample of peripheral blood for molecular analysis and were examined by a single physician who 
reported data on pigmentation, nevi and other skin characteristics. All participants provided written 
informed consent and responded to an interview-based questionnaire on melanoma risk factors and 
the study was approved by the local Institutional Review Board.
 
Genoa – The Genoa Study
The Genoa study is a hospital based case-control study conducted at the Genetics of Rare Cancers 
Unit at the San Martino University Hospital in Genoa, Italy and IRCCS AOU San Martino-IST 
Research Hospital88-91. Cases were cutaneous melanoma patients recruited over the past 15 years 
referred for clinical genetic testing. Cases were either sporadic or affected by multiple primary 
melanoma or were probands from melanoma families. All cases were 18 years of age or older with 
a histologically confirmed in situ or invasive cutaneous melanoma. Controls were healthy 
volunteers or spouses 18 years old or older who were recruited in the same period as the cases and 
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matched by gender, age and place of residence. Participants donated a sample of peripheral blood 
for molecular analyses as well as filled out a detailed questionnaire on hair, eye and skin color, sun 
exposure, and history of melanoma. A trained interviewer also assessed presence of freckles and 
nevi. All participants provided written informed consent and the study was approved by the Ethics 
Committees of the participating Institutions.
 
L’Aquila
The Department of Dermatology of the University of L’Aquila, Italy recruited familial and sporadic
melanoma cases and controls for study participation85,92-94. Familial melanoma cases were defined as
patients from melanoma families with at least 2 first- or second-degree relatives or with at least 3 
documented cases of melanoma irrespective of the degree of relatedness. Sporadic melanoma cases 
were defined as patients consecutively presenting with histopathologically confirmed sporadic 
primary cutaneous melanoma of any stage either as a first diagnosis or during the periodic follow-
up. Controls were individuals free of melanoma at time of study entry. Only controls related to 
sporadic melanoma patients were recruited. Control individuals were matched to cases by gender, 
age (within 1 year), ethnicity and residential area and were consecutively recruited in the same 
period from patients with allergic disorders, skin infections, psoriasis, ulcers or autoimmune 
diseases referred to the same department. All sporadic and familial melanoma patients and control 
individuals were of Italian origin. Basic demographic information and phenotypic characteristics of 
patients were collected through a standardized questionnaire. Skin examination was performed by a 
dermatologist who evaluated skin type, hair color, eye color, number of melanocytic nevi and 
presence or absence of clinically atypical nevi. All participants signed an informed consent form 
and the local Institutional Review Board approved the study.
 
Milano
The Milano study is a case-control study conducted at the Fondazione IRCCS Istituto Nazionale 
Tumori in Milan, Italy. Melanoma cases were defined as patients hospitalized for surgical treatment
of melanoma at the Melanoma and Sarcoma Surgery Unit. All cases of melanoma were confirmed 
by histopathology. Controls were melanoma free at study entry and recruited from healthy blood 
donors from the Immunohematology and Transfusion Medicine Unit. No matching of controls to 
cases was performed. Phototype information was obtained by a self-administered questionnaire. 
Atypical nevi and phototypes were defined by a single clinician. All participants signed an informed
consent form and the local Institutional Review Board approved the study.
 
Padua
The Padua study is comprised of melanoma-prone families with at least 2 melanoma cases referred 
to the Veneto Institute of Oncology (IOV) in Padua, Italy95,96. All cases of melanoma were 
confirmed by pathology reports. Family history and phenotypic features were obtained from 
personal interviews using a standardized questionnaire. Self-reported hair/eye/skin colour was 
recorded using reference colour classes. Presence/absence of freckles and nevus count were defined 
according to physical examination by a trained dermatologist. Control participants were healthy 
individuals without personal or family history of melanoma who were donors at the Blood 
Collection Center, Hospital Transfusion Centre of Padua. All melanoma patients and control 
individuals were of Caucasian origin and living in Veneto, a region in the North-East Italy. Written 
informed consent was obtained by all participants enrolled in the study and the project was 
approved by the institutional local ethical committee.
 
Roma
The Roma study is a series of familial and sporadic melanoma cases recruited from the Institute of 
Dermatology, Catholic University Rome, Italy since 2014. Familial melanoma cases were defined 
as patients from melanoma families with at least 2 first- or second-degree relatives or with at least 3
documented cases of melanoma irrespective of the degree of relatedness. Sporadic cases were 
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defined as patients consecutively presenting with histopathologically confirmed sporadic primary 
cutaneous melanoma of any stage either as a first diagnosis or during the periodic follow-up. All 
cases were confirmed by histopathological review of melanoma tissue slides. No controls were 
recruited that were related to sporadic melanoma patients. A standardized questionnaire was 
administered by physicians trained in data gathering to collect demographic information and 
phenotypic characteristics. Skin examination was performed by a dermatologist who evaluated skin 
type, hair color, eye color, number of melanocytic nevi and presence or absence of clinically 
atypical nevi. All participants signed an informed consent form and the local Institutional Review 
Board approved the study.
 
Valencia
The Valencia study consists of sporadic cases, familial cases and melanoma-free controls97.
The sporadic cases consisted of Spanish cutaneous melanoma patients recruited at the Department 
of Dermatology, Instituto Valenciano de Oncologia, a referral skin cancer center for the provinces 
of Valencia, Alicante and Castellon, with a catchment population of approximately 5 million 
people. All cases are histopathologically confirmed melanoma cases by an expert pathologist 
devoted to skin cancer pathology and were treated at the center. Clinical and pathological data from 
the patients were prospectively collected since January 2000 through the review of medical history, 
personal interview and clinical examination by expert dermatologists. Controls are disease free and 
ethnically matched blood donors recruited at the Transfusion Center of Valencia between 
September 2008 and January 2009. All the epidemiological and phenotypic characteristics of skin 
were obtained from a structured questionnaire performed at the time of blood sampling. All 
participants signed an informed consent form and the local Institutional Review Board approved the
study.
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